US Patent

US8680111 — Macrocyclic derivatives for the treatment of diseases

Composition of Matter · Assigned to Pfizer Inc · Expires 2033-03-05 · 7y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK for treating or ameliorating abnormal cell proliferative disorders such as cancer.

USPTO Abstract

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US8680111
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-03-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.